Chemical genomics-based drug discovery platform
Infinity is a clinical-stage company focused on developing new medicines for the treatment of cancer.
CEO Adelene Q. Perkins
Advent Contact Shahzad Malik
Advent invested in 2002. Infinity listed in 2009 (NASDAQ:INFI).
Exited Investments
Infinity announces that Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity’s FAAH Pain Program Worldwide
Press Release. Decision Demonstrates Strength of Alliance and Underscores Complementary Capabilities of the Partners CAMBRIDGE, Mass., -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Purdue Pharmaceutical Products L.P.…
Read More
Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors
Press Release. First Demonstration of Clinical Activity of IPI-926 Observed in Patients With Basal Cell Carcinoma MILAN, Italy -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced promising preliminary results…
Read More
Infinity Pharmaceuticals strikes major alliance to fully fund promising pipeline
Press Release. Infinity Announces Global Strategic Alliance With Purdue Pharma and Mundipharma Encompassing Infinity's Early Clinical and Discovery Programs Infinity Retains All U.S. Rights; Mundipharma Receives Ex-U.S. Commercialization Rights…
Read More
